Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High – Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $48.79 and last traded at $48.60, with a volume of 1927396 shares changing hands. The stock had previously closed at $45.96.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho raised their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Stifel Nicolaus initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright upped their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, The Goldman Sachs Group upped their target price on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $63.40.

Enliven Therapeutics Trading Up 5.7%

The business has a 50 day moving average of $41.82 and a 200-day moving average of $31.76. The stock has a market cap of $2.96 billion, a PE ratio of -29.10 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Research analysts expect that Enliven Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director owned 51,884 shares in the company, valued at $1,792,073.36. This represents a 16.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently made changes to their positions in the business. Commodore Capital LP grew its holdings in shares of Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares during the last quarter. Vestal Point Capital LP raised its stake in Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc raised its stake in Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after acquiring an additional 418,673 shares during the last quarter. Vanguard Group Inc. lifted its position in Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after acquiring an additional 142,378 shares during the period. Finally, State Street Corp lifted its position in Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after acquiring an additional 87,725 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.